Class Action Filed Against Embecta Corp. by Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Robbins LLP informs all investors who purchased or acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025, and May 4, 2026, that a class action has been filed, alleging the company misled investors regarding its business prospects.
- Performance Miss: According to the complaint, Embecta's second-quarter 2026 fiscal results revealed a revenue decline of over 14%, significantly worse than the guidance of flat to a 2% decline, indicating weakness in pen needle sales and leading to a downward revision of its full-year outlook.
- Stock Price Reaction: Following the disappointing earnings announcement on May 5, 2026, Embecta's stock price fell to $3.90 per share, reflecting market disappointment and a decline in trust towards the management's guidance.
- Investor Action: Robbins LLP encourages shareholders to participate in the class action, with the lead plaintiff representing the group in directing the litigation, allowing investors to potentially recover losses without needing to actively participate in the case, emphasizing the importance of corporate governance and executive accountability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: Robbins LLP informs all investors who purchased or acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025, and May 4, 2026, that a class action has been filed, alleging the company misled investors regarding its business prospects.
- Performance Miss: According to the complaint, Embecta's second-quarter 2026 fiscal results revealed a revenue decline of over 14%, significantly worse than the guidance of flat to a 2% decline, indicating weakness in pen needle sales and leading to a downward revision of its full-year outlook.
- Stock Price Reaction: Following the disappointing earnings announcement on May 5, 2026, Embecta's stock price fell to $3.90 per share, reflecting market disappointment and a decline in trust towards the management's guidance.
- Investor Action: Robbins LLP encourages shareholders to participate in the class action, with the lead plaintiff representing the group in directing the litigation, allowing investors to potentially recover losses without needing to actively participate in the case, emphasizing the importance of corporate governance and executive accountability.
See More
- Lawsuit Deadline: The Law Offices of Howard G. Smith remind investors that the deadline to file a lead plaintiff motion is August 17, 2026, for those who purchased Embecta Corp. stock between November 25, 2025, and May 4, 2026.
- Declining Financial Performance: On May 5, 2026, Embecta reported a revenue decline of over 14% in its second-quarter results, primarily due to weak pen needle sales, prompting the company to lower its guidance for the remainder of fiscal 2026.
- Stock Price Plunge: Following the financial report, Embecta's stock price fell by $5.35, or 57.8%, closing at $3.90 per share on May 5, 2026, resulting in significant losses for investors.
- False Statements Allegation: The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, misleading investors significantly.
See More
- Lawsuit Background: Bernstein Liebhard LLP announced that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased Embecta Corp. stock between November 25, 2025, and May 4, 2026, alleging significant false statements regarding the company's operations and financial stability.
- Investor Action Recommendation: Investors are encouraged to promptly submit a form to participate in the lawsuit, and those wishing to serve as lead plaintiff must file papers by August 17, 2026; absent members may not share in any recovery if they choose not to act.
- Loss Impact: The lawsuit claims that due to the company's alleged misrepresentations, Embecta's stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, indicating potential financial and reputational risks for the company.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its strong capabilities in securities litigation.
See More

- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit due to its disastrous Q2 2026 earnings report, which has prompted significant investor disappointment, representing those who purchased stock between November 25, 2025, and May 4, 2026.
- Deteriorating Financial Performance: The company reported an adjusted EPS of only $0.27 for Q2 2026, reflecting a staggering 61% year-over-year decline, starkly contrasting with its previous guidance of $2.80 to $3.00 for 2026, indicating severe weaknesses in its core product market.
- Significant Dividend Cut: Embecta slashed its 2026 dividend by 93% to just $0.01, signaling a major shift in its capital allocation strategy under financial pressure, which may further erode investor confidence.
- Investigation Initiated: Hagens Berman has launched an investigation into whether Embecta's management was aware of market weaknesses prior to the earnings report and failed to adequately disclose these risks, potentially impacting the company's future transparency and investor trust.
See More
- Stock Plunge: Embecta's shares plummeted 57.8% on May 5, 2026, dropping from $9.25 to $3.90, representing a loss of $5.35 per share, which raises serious concerns about the company's financial health among investors.
- Customer Concentration Risk: The lawsuit alleges that management concealed significant market share losses at a single major customer, resulting in revenue impacts that far exceeded expectations and undermined the company's competitive position in the U.S. market.
- Retail Channel Weakness: In addition to customer concentration risks, the lawsuit contends that overall market softness for insulin pens and pen needles led patients to purchase from other channels, creating additional sales pressure that management failed to disclose in a timely manner.
- Lack of Transparency: The lawsuit emphasizes that investors deserve transparency regarding material risks that could affect their investments, as management did not adequately communicate competitive and channel dynamics, leading to a significant stock price drop upon reevaluation.
See More
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) for stock purchasers between November 25, 2025, and May 4, 2026, aiming to seek compensation for investors, highlighting serious issues in the company's financial disclosures.
- Lawsuit Context: The lawsuit alleges that Embecta made false or misleading statements regarding its fiscal performance, particularly in its 2026 guidance, resulting in investor losses when the true situation emerged, indicating a lack of governance and transparency within the company.
- Investor Rights Protection: Investors can apply to be lead plaintiffs by August 17, 2026, to participate in the lawsuit without any upfront costs, reflecting the accessibility of legal services and the emphasis on protecting investor rights.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and influence in advocating for investor rights.
See More





